• +1-646-491-9876
    • +91-20-67278686

    Search

    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016

    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016

    • Report Code ID: RW0001506643
    • Category Pharmaceuticals
    • No. of Pages 123
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's, 'Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted pipeline therapeutics.

    The report provides comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Report Scope

    - The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
    - The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents 2
    List of Tables 7
    List of Figures 8
    Introduction 9
    Publisher Report Coverage 9
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Overview 10
    Therapeutics Development 11
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Stage of Development 11
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Therapy Area 12
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Indication 13
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Products Glance 15
    Late Stage Products 15
    Early Stage Products 16
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Companies 17
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Universities/Institutes 21
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Therapeutics Assessment 23
    Assessment by Monotherapy/Combination Products 23
    Assessment by Mechanism of Action 24
    Assessment by Route of Administration 26
    Assessment by Molecule Type 28
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30
    Amgen Inc. 30
    Antisense Therapeutics Limited 31
    Astellas Pharma Inc. 32
    AstraZeneca Plc 33
    Axelar AB 34
    Boehringer Ingelheim GmbH 35
    Eli Lilly and Company 36
    F. Hoffmann-La Roche Ltd. 37
    Genmab A/S 38
    Immunomedics, Inc. 39
    Insmed Incorporated 40
    Merck & Co., Inc. 41
    Merrimack Pharmaceuticals, Inc. 42
    Novartis AG 43
    PharmAbcine, Inc. 44
    Prometheon Pharma, LLC 45
    ProteoThera, Inc. 46
    Silver Creek Pharmaceuticals, Inc. 47
    Sucampo Pharmaceuticals, Inc. 48
    TyrNovo Ltd. 49
    XL-protein GmbH 50
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drug Profiles 51
    1R-15-15 - Drug Profile 51
    Product Description 51
    Mechanism Of Action 51
    R&D Progress 51
    1R-2b - Drug Profile 52
    Product Description 52
    Mechanism Of Action 52
    R&D Progress 52
    1R-3s - Drug Profile 53
    Product Description 53
    Mechanism Of Action 53
    R&D Progress 53
    1R-E1-E1 - Drug Profile 54
    Product Description 54
    Mechanism Of Action 54
    R&D Progress 54
    ATL-1101 - Drug Profile 55
    Product Description 55
    Mechanism Of Action 55
    R&D Progress 55
    AXL-1717 - Drug Profile 57
    Product Description 57
    Mechanism Of Action 57
    R&D Progress 57
    AZD-3463 - Drug Profile 59
    Product Description 59
    Mechanism Of Action 59
    R&D Progress 59
    BI-893923 - Drug Profile 60
    Product Description 60
    Mechanism Of Action 60
    R&D Progress 60
    CT-707 - Drug Profile 61
    Product Description 61
    Mechanism Of Action 61
    R&D Progress 61
    dalotuzumab - Drug Profile 62
    Product Description 62
    Mechanism Of Action 62
    R&D Progress 62
    Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 64
    Product Description 64
    Mechanism Of Action 64
    R&D Progress 64
    ganitumab - Drug Profile 65
    Product Description 65
    Mechanism Of Action 65
    R&D Progress 65
    Hex-hR1 - Drug Profile 68
    Product Description 68
    Mechanism Of Action 68
    R&D Progress 68
    istiratumab - Drug Profile 69
    Product Description 69
    Mechanism Of Action 69
    R&D Progress 69
    lenaldekar - Drug Profile 71
    Product Description 71
    Mechanism Of Action 71
    R&D Progress 71
    linsitinib - Drug Profile 72
    Product Description 72
    Mechanism Of Action 72
    R&D Progress 72
    M-590 - Drug Profile 74
    Product Description 74
    Mechanism Of Action 74
    R&D Progress 74
    mecasermin rinfabate - Drug Profile 75
    Product Description 75
    Mechanism Of Action 75
    R&D Progress 75
    Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile 78
    Product Description 78
    Mechanism Of Action 78
    R&D Progress 78
    Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile 79
    Product Description 79
    Mechanism Of Action 79
    R&D Progress 79
    NT-157 - Drug Profile 80
    Product Description 80
    Mechanism Of Action 80
    R&D Progress 80
    NT-219 - Drug Profile 81
    Product Description 81
    Mechanism Of Action 81
    R&D Progress 81
    Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 82
    Product Description 82
    Mechanism Of Action 82
    R&D Progress 82
    Protein to Agonize Insulin Like Growth Factor 1 Receptor for Hormone Replacement Therapy - Drug Profile 83
    Product Description 83
    Mechanism Of Action 83
    R&D Progress 83
    Recombinant Insulin Like Growth Factor 1 - Drug Profile 84
    Product Description 84
    Mechanism Of Action 84
    R&D Progress 84
    Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 85
    Product Description 85
    Mechanism Of Action 85
    R&D Progress 85
    Recombinant Protein to Antagonize IGF-1R for Oncology - Drug Profile 86
    Product Description 86
    Mechanism Of Action 86
    R&D Progress 86
    Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile 87
    Product Description 87
    Mechanism Of Action 87
    R&D Progress 87
    RU-105 - Drug Profile 88
    Product Description 88
    Mechanism Of Action 88
    R&D Progress 88
    Small Molecule to Antagonize IGF-1R for Oncology - Drug Profile 89
    Product Description 89
    Mechanism Of Action 89
    R&D Progress 89
    Small Molecules to Antagonize IGF-1R for Oncology - Drug Profile 90
    Product Description 90
    Mechanism Of Action 90
    R&D Progress 90
    Small Molecules to Inhibit IGF-1R/IR for Oncology - Drug Profile 91
    Product Description 91
    Mechanism Of Action 91
    R&D Progress 91
    Small Molecules to Inhibit IGF1R for Breast Cancer - Drug Profile 92
    Product Description 92
    Mechanism Of Action 92
    R&D Progress 92
    teprotumumab - Drug Profile 93
    Product Description 93
    Mechanism Of Action 93
    R&D Progress 93
    Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer - Drug Profile 95
    Product Description 95
    Mechanism Of Action 95
    R&D Progress 95
    vesiculin - Drug Profile 96
    Product Description 96
    Mechanism Of Action 96
    R&D Progress 96
    XGFR-2 - Drug Profile 97
    Product Description 97
    Mechanism Of Action 97
    R&D Progress 97
    XGFR-4 - Drug Profile 98
    Product Description 98
    Mechanism Of Action 98
    R&D Progress 98
    XL-110 - Drug Profile 99
    Product Description 99
    Mechanism Of Action 99
    R&D Progress 99
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Dormant Projects 100
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Discontinued Products 107
    Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Featured News & Press Releases 111
    Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants 111
    Mar 16, 2016: Merrimack to Present on MM-141 (istiratumab) at the 2016 American Association for Cancer Research Annual Meeting 112
    Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 112
    May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 113
    Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 113
    Mar 17, 2015: Study suggests precision medicine for adrenal cancer 115
    Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 116
    Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer 117
    Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting 117
    Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics 118
    Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer 119
    Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer 120
    Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 120
    Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease 121
    Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy 121
    Appendix 122
    Methodology 122
    Coverage 122
    Secondary Research 122
    Primary Research 122
    Expert Panel Validation 122
    Contact Us 122
    Disclaimer 123

    List of Tables

    Number of Products under Development for, H2 2016 11
    Number of Products under Development by Therapy Area, H2 2016 12
    Number of Products under Development by Indication, H2 2016 13
    Comparative Analysis by Late Stage Development, H2 2016 15
    Comparative Analysis by Early Stage Products, H2 2016 16
    Number of Products under Development by Companies, H2 2016 17
    Products under Development by Companies, H2 2016 18
    Products under Development by Companies, H2 2016 (Contd..1) 19
    Products under Development by Companies, H2 2016 (Contd..2) 20
    Number of Products under Investigation by Universities/Institutes, H2 2016 21
    Products under Investigation by Universities/Institutes, H2 2016 22
    Assessment by Monotherapy/Combination Products, H2 2016 23
    Number of Products by Stage and Mechanism of Action, H2 2016 25
    Number of Products by Stage and Route of Administration, H2 2016 27
    Number of Products by Stage and Molecule Type, H2 2016 29
    Pipeline by Amgen Inc., H2 2016 30
    Pipeline by Antisense Therapeutics Limited, H2 2016 31
    Pipeline by Astellas Pharma Inc., H2 2016 32
    Pipeline by AstraZeneca Plc, H2 2016 33
    Pipeline by Axelar AB, H2 2016 34
    Pipeline by Boehringer Ingelheim GmbH, H2 2016 35
    Pipeline by Eli Lilly and Company, H2 2016 36
    Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 37
    Pipeline by Genmab A/S, H2 2016 38
    Pipeline by Immunomedics, Inc., H2 2016 39
    Pipeline by Insmed Incorporated, H2 2016 40
    Pipeline by Merck & Co., Inc., H2 2016 41
    Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 42
    Pipeline by Novartis AG, H2 2016 43
    Pipeline by PharmAbcine, Inc., H2 2016 44
    Pipeline by Prometheon Pharma, LLC, H2 2016 45
    Pipeline by ProteoThera, Inc., H2 2016 46
    Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016 47
    Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 48
    Pipeline by TyrNovo Ltd., H2 2016 49
    Pipeline by XL-protein GmbH, H2 2016 50
    Dormant Projects, H2 2016 100
    Dormant Projects (Contd..1), H2 2016 101
    Dormant Projects (Contd..2), H2 2016 102
    Dormant Projects (Contd..3), H2 2016 103
    Dormant Projects (Contd..4), H2 2016 104
    Dormant Projects (Contd..5), H2 2016 105
    Dormant Projects (Contd..6), H2 2016 106
    Discontinued Products, H2 2016 107
    Discontinued Products (Contd..1), H2 2016 108
    Discontinued Products (Contd..2), H2 2016 109
    Discontinued Products (Contd..3), H2 2016 110

    List of Figures

    Number of Products under Development for, H2 2016 11
    Number of Products under Development by Therapy Area, H2 2016 12
    Number of Products under Development by Top 10 Indication, H2 2016 13
    Comparative Analysis by Early Stage Products, H2 2016 16
    Assessment by Monotherapy/Combination Products, H2 2016 23
    Number of Products by Mechanism of Actions, H2 2016 24
    Number of Products by Stage and Mechanism of Actions, H2 2016 24
    Number of Products by Routes of Administration, H2 2016 26
    Number of Products by Stage and Routes of Administration, H2 2016 26
    Number of Products by Molecule Types, H2 2016 28
    Number of Products by Stage and Molecule Type, H2 2016 28
    Amgen Inc.
    Antisense Therapeutics Limited
    Astellas Pharma Inc.
    AstraZeneca Plc
    Axelar AB
    Boehringer Ingelheim GmbH
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd.
    Genmab A/S
    Immunomedics, Inc.
    Insmed Incorporated
    Merck & Co., Inc.
    Merrimack Pharmaceuticals, Inc.
    Novartis AG
    PharmAbcine, Inc.
    Prometheon Pharma, LLC
    ProteoThera, Inc.
    Silver Creek Pharmaceuticals, Inc.
    Sucampo Pharmaceuticals, Inc.
    TyrNovo Ltd.
    XL-protein GmbH

    Request for Sample

    Report Url http://www.reportsweb.com//insulin-like-growth-factor-1-receptor-cd221-or-igf1r-or-ec-2-7-10-1-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//insulin-like-growth-factor-1-receptor-cd221-or-igf1r-or-ec-2-7-10-1-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//insulin-like-growth-factor-1-receptor-cd221-or-igf1r-or-ec-2-7-10-1-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments